[go: up one dir, main page]

MX2018004114A - Compuestos terapeuticos y metodos. - Google Patents

Compuestos terapeuticos y metodos.

Info

Publication number
MX2018004114A
MX2018004114A MX2018004114A MX2018004114A MX2018004114A MX 2018004114 A MX2018004114 A MX 2018004114A MX 2018004114 A MX2018004114 A MX 2018004114A MX 2018004114 A MX2018004114 A MX 2018004114A MX 2018004114 A MX2018004114 A MX 2018004114A
Authority
MX
Mexico
Prior art keywords
domain
methods
therapeutic compounds
compounds
target
Prior art date
Application number
MX2018004114A
Other languages
English (en)
Other versions
MX389194B (es
Inventor
Attilio Vallera Daniel
S Miller Jeffrey
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2018004114A publication Critical patent/MX2018004114A/es
Publication of MX389194B publication Critical patent/MX389194B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C07K16/114—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a compuestos diseñados por ingeniería genética que se acoplan a células NK y métodos para usar los compuestos. En general, el compuesto incluye un dominio de acoplamiento a NK, un dominio de objetivo que se une selectivamente a una célula objetivo, y un dominio de activación de NK que enlaza operablemente el dominio de acoplamiento a NK y el dominio de objetivo.
MX2018004114A 2015-10-06 2016-10-06 Compuestos terapéuticos y métodos. MX389194B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237835P 2015-10-06 2015-10-06
PCT/US2016/055722 WO2017062604A1 (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Publications (2)

Publication Number Publication Date
MX2018004114A true MX2018004114A (es) 2018-08-21
MX389194B MX389194B (es) 2025-03-20

Family

ID=58488527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004114A MX389194B (es) 2015-10-06 2016-10-06 Compuestos terapéuticos y métodos.

Country Status (12)

Country Link
US (4) US11098100B2 (es)
EP (2) EP3359168A4 (es)
JP (3) JP7461620B2 (es)
KR (1) KR102716215B1 (es)
CN (1) CN108697736A (es)
AU (2) AU2016336451B2 (es)
BR (1) BR112018006811A2 (es)
IL (1) IL258931B (es)
MX (1) MX389194B (es)
RU (1) RU2770001C2 (es)
SG (2) SG10201912792YA (es)
WO (1) WO2017062604A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200353T1 (it) 2015-02-06 2022-09-14 Nat Univ Singapore Metodi per aumentare l’efficacia di cellule immunitarie terapeutiche
RU2770001C2 (ru) 2015-10-06 2022-04-14 Риджентс Оф Дзе Юниверсити Оф Миннесота Терапевтические соединения и способы
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2019032916A1 (en) 2017-08-10 2019-02-14 National University Of Singapore CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTES WITH LYMPHOCYTE T-RECEPTOR DEFICIENTS AND METHODS OF USE THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
AU2018385409A1 (en) * 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US12319737B2 (en) 2018-10-19 2025-06-03 Regents Of The University Of Minnesota NK engager molecules and methods of use thereof
JP7630426B2 (ja) 2018-10-23 2025-02-17 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224680B2 (en) * 2019-02-21 2025-06-19 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
US20220213489A1 (en) * 2019-05-31 2022-07-07 City Of Hope Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
EP3983017A4 (en) * 2019-06-12 2023-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methods to treat viral infections
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
AU2020350524A1 (en) * 2019-09-16 2022-04-21 Gt Biopharma, Inc. Immunotherapy compounds and methods
CN114502577A (zh) * 2019-09-26 2022-05-13 明尼苏达大学董事会 结合病毒抗原的nk接合器化合物和使用方法
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2021138407A2 (en) * 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116096353A (zh) 2020-04-22 2023-05-09 蜻蜓疗法股份有限公司 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺
BR112022024768A2 (pt) * 2020-06-03 2022-12-27 Univ Minnesota Proteínas de alvejamento a b7h3 e métodos de uso das mesmas
WO2022150379A1 (en) * 2021-01-08 2022-07-14 Regents Of The University Of Minnesota Nk cell engager molecules and methods of use
CN116574190A (zh) * 2021-07-30 2023-08-11 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023225531A2 (en) * 2022-05-16 2023-11-23 Northwestern University Il15-modified car t cells for dual targeting
IL317214A (en) * 2022-05-31 2025-01-01 Oncopeptides Innovation 1 Ab New polypeptides
JP2025534206A (ja) 2022-09-15 2025-10-15 アビディキュア アイピー ビー．ブイ． Ｎｋ細胞を刺激するための多重特異性抗原結合タンパク質及びその使用
WO2024064446A2 (en) * 2022-09-19 2024-03-28 Duke University Compositions and methods for the enhancement of immune cell activities against cancer
CN118909134A (zh) * 2023-05-06 2024-11-08 北京新合睿恩生物医疗科技有限公司 IL-15融合蛋白及其mRNA序列和应用
AU2024273560A1 (en) * 2023-05-12 2025-11-27 Christian-Albrechts-Universität Zu Kiel Means and methods for the expansion of nk-cells
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
CN100473664C (zh) 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
EA200501019A1 (ru) 2002-12-20 2006-06-30 Байоджен Айдек Эмэй Инк. Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005089788A1 (ja) * 2004-03-19 2005-09-29 Morinaga Milk Industry Co., Ltd. 癌治療のための薬剤
JP4949373B2 (ja) 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
EP2450702A3 (en) 2007-01-26 2012-07-25 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
CA2697529A1 (en) 2007-08-24 2009-03-05 Regents Of The University Of Minnesota Receptor-targeting reagents
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012017522A1 (ja) 2010-08-03 2012-02-09 富士通株式会社 検証プログラムおよび検証装置
AU2011305476B2 (en) * 2010-09-21 2016-12-01 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
DK2714735T3 (da) 2011-06-03 2021-10-18 Xoma Technology Ltd Antistoffer, der er specifikke for TGF-beta
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012309824A1 (en) 2011-09-12 2013-04-18 Abbvie Biotherapeutics Inc. Artificial NK cells and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US9258177B2 (en) * 2012-08-02 2016-02-09 International Business Machines Corporation Storing a data stream in a set of storage devices
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
RU2770001C2 (ru) 2015-10-06 2022-04-14 Риджентс Оф Дзе Юниверсити Оф Миннесота Терапевтические соединения и способы

Also Published As

Publication number Publication date
CN108697736A (zh) 2018-10-23
AU2016336451B2 (en) 2023-06-29
SG11201802794PA (en) 2018-05-30
JP2022037037A (ja) 2022-03-08
US11098101B2 (en) 2021-08-24
EP3359168A1 (en) 2018-08-15
AU2023233318A1 (en) 2023-10-12
IL258931A (en) 2018-06-28
EP3359168A4 (en) 2019-08-07
SG10201912792YA (en) 2020-02-27
IL258931B (en) 2022-09-01
US20210395326A1 (en) 2021-12-23
AU2016336451A1 (en) 2018-04-26
JP2018531939A (ja) 2018-11-01
CA3001185A1 (en) 2017-04-13
JP7274781B2 (ja) 2023-05-17
KR20180057715A (ko) 2018-05-30
RU2018116565A (ru) 2019-11-07
WO2017062604A1 (en) 2017-04-13
JP7555625B2 (ja) 2024-09-25
JP2023089290A (ja) 2023-06-27
US20200148737A1 (en) 2020-05-14
RU2018116565A3 (es) 2020-11-03
JP7461620B2 (ja) 2024-04-04
KR102716215B1 (ko) 2024-10-10
MX389194B (es) 2025-03-20
BR112018006811A2 (en) 2018-10-16
US20200087369A1 (en) 2020-03-19
US20180282386A1 (en) 2018-10-04
RU2770001C2 (ru) 2022-04-14
US11098100B2 (en) 2021-08-24
EP4056190A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
MX2018004114A (es) Compuestos terapeuticos y metodos.
CL2019002307A1 (es) Polipéptidos de unión al receptor de transferrina diseñados.
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
BR112019012343A2 (pt) anticorpos il-11ra
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
BR112019012342A2 (pt) anticorpos il-11
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
EA201891211A1 (ru) Ингибиторы cxcr2
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
AR106583A1 (es) Anticuerpos que se unen específicamente a pd-1, tim-3 o pd-1 y tim-3 y sus usos
CR20160294A (es) Un panel para mobiliario
CO2017003005A2 (es) Anticuerpos anti-mfi2
MX2018001398A (es) Anticuerpos monoclonales contra bcma.
MX384883B (es) Métodos para usar activadores de piruvato cinasa.
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
CR20160419A (es) Nuevos compuestos biciclicos
BR112018008877A2 (pt) inibidores de ret
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
DK3105190T3 (da) Behandling af tilbagediffusion af grundvandsmagasinmatrix
EA201700136A1 (ru) Полимерная композиция для слоя элемента слоя
BR112019010131A2 (pt) entrega transdérmica de agentes grandes